Taiwan · Delayed Price · Currency is TWD Bonraybio Statistics
Total Valuation
Bonraybio has a market cap or net worth of TWD 4.12 billion. The enterprise value is 3.57 billion.
| Market Cap | 4.12B |
| Enterprise Value | 3.57B |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | Mar 19, 2026 |
Share Statistics
Bonraybio has 24.80 million shares outstanding. The number of shares has increased by 9.08% in one year.
| Current Share Class | 24.80M |
| Shares Outstanding | 24.80M |
| Shares Change (YoY) | +9.08% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 2.73% |
| Float | 10.55M |
Valuation Ratios
The trailing PE ratio is 40.29.
| PE Ratio | 40.29 |
| Forward PE | n/a |
| PS Ratio | 13.44 |
| PB Ratio | 6.42 |
| P/TBV Ratio | 6.67 |
| P/FCF Ratio | 50.56 |
| P/OCF Ratio | 41.17 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 31.78, with an EV/FCF ratio of 43.79.
| EV / Earnings | 34.79 |
| EV / Sales | 11.64 |
| EV / EBITDA | 31.78 |
| EV / EBIT | 35.67 |
| EV / FCF | 43.79 |
Financial Position
The company has a current ratio of 8.71, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.71 |
| Quick Ratio | 8.01 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.20 |
| Debt / FCF | 0.27 |
| Interest Coverage | 757.20 |
Financial Efficiency
Return on equity (ROE) is 16.90% and return on invested capital (ROIC) is 107.13%.
| Return on Equity (ROE) | 16.90% |
| Return on Assets (ROA) | 9.31% |
| Return on Invested Capital (ROIC) | 107.13% |
| Return on Capital Employed (ROCE) | 15.49% |
| Weighted Average Cost of Capital (WACC) | 4.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.96 |
Taxes
In the past 12 months, Bonraybio has paid 2.27 million in taxes.
| Income Tax | 2.27M |
| Effective Tax Rate | 2.17% |
Stock Price Statistics
The stock price has increased by +15.35% in the last 52 weeks. The beta is 0.03, so Bonraybio's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | +15.35% |
| 50-Day Moving Average | 165.54 |
| 200-Day Moving Average | 160.19 |
| Relative Strength Index (RSI) | 47.59 |
| Average Volume (20 Days) | 12,530 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bonraybio had revenue of TWD 306.31 million and earned 102.51 million in profits. Earnings per share was 4.12.
| Revenue | 306.31M |
| Gross Profit | 238.52M |
| Operating Income | 99.95M |
| Pretax Income | 104.78M |
| Net Income | 102.51M |
| EBITDA | 108.95M |
| EBIT | 99.95M |
| Earnings Per Share (EPS) | 4.12 |
Balance Sheet
The company has 573.25 million in cash and 21.95 million in debt, with a net cash position of 551.29 million or 22.23 per share.
| Cash & Cash Equivalents | 573.25M |
| Total Debt | 21.95M |
| Net Cash | 551.29M |
| Net Cash Per Share | 22.23 |
| Equity (Book Value) | 641.41M |
| Book Value Per Share | 25.86 |
| Working Capital | 576.11M |
Cash Flow
In the last 12 months, operating cash flow was 99.99 million and capital expenditures -18.57 million, giving a free cash flow of 81.42 million.
| Operating Cash Flow | 99.99M |
| Capital Expenditures | -18.57M |
| Depreciation & Amortization | 9.00M |
| Net Borrowing | 11.74M |
| Free Cash Flow | 81.42M |
| FCF Per Share | 3.28 |
Margins
Gross margin is 77.87%, with operating and profit margins of 32.63% and 33.46%.
| Gross Margin | 77.87% |
| Operating Margin | 32.63% |
| Pretax Margin | 34.21% |
| Profit Margin | 33.46% |
| EBITDA Margin | 35.57% |
| EBIT Margin | 32.63% |
| FCF Margin | 26.58% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.90%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 0.90% |
| Dividend Growth (YoY) | 15.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 31.56% |
| Buyback Yield | -9.08% |
| Shareholder Yield | -8.17% |
| Earnings Yield | 2.49% |
| FCF Yield | 1.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 25, 2025. It was a forward split with a ratio of 1.15.
| Last Split Date | Aug 25, 2025 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
Bonraybio has an Altman Z-Score of 30.25 and a Piotroski F-Score of 3.
| Altman Z-Score | 30.25 |
| Piotroski F-Score | 3 |